Background: In adoptive T cell therapy (ACT), one of the greatest challenges is the recruitment of T cells to tumor tissue. T cells, engineered with chimeric antigen receptors (CAR) haven proven efficacy for hematological malignancies but at the same time induce severe side effects such as cytokine release syndrome. We herein describe a novel MHC-unrestricted modular platform by combining autologous T cells, transduced with a targetable synthetic agonistic receptor (SAR), with crosslinking bispecific antibodies (BiAb) that specifically recruit and activate T cells to the tumor tissue.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
P07. Adoptive cell therapy P07.01
© 2018 Published by Elsevier Inc.